Tekturna Side Effects

Causing Strokes and Kidney Failure

The national Tekturna pharmaceutical law firm of Nadrich & Cohen are reviewing cases involving the blood pressure drug Tekturna and:

• Tekamlo
• Tekturna HCT.

These are blood pressure drugs manufactured by Novartis and given to patients for high blood pressure. Sadly, the drug can cause serious kidney complications including kidney failure. We are investigating kidney failure cases throughout the country. Tekturna is a hypertension drug known as a Renin Inhibitor. It is believed to be able to narrow the blood vessels in order to regulate blood pressure. Sadly, it can also cause liver failure and other serious kidney complications. One early study of patients was stopped halfway because of the significant risks of kidney damage, renal complications, non-fatal strokes, hypotension and hyperkalemia.

In December 2011 Novartis publicly stated that Tekturna should not be given to patients who are taking an ACE inhibitor or an ARB. Our information is that Novartis is no longer promoting Tekturna.

Please contact us if you have suffered kidney failure. We have tremendous knowledge concerning kidney problems, kidney failure, kidney complications.

On April 20th, 2012, the Food and Drug Administration (“FDA”) published a press release entitled, “Safety Alerts” which included additional warnings for the blood pressure medication known as Tekturna which contains Aliskiren - the active ingredient. Tekturna is an FDA approved drug taken orally and prescribed to treat high blood pressure (hypertension). It is manufactured by Novartis. Side effects of this product include:

• Stroke
• Kidney Failure

If you or a loved one has taken Tekturna and suffered kidney failure, kidney injury, cardiac injury or stroke please contact one of our qualified intake specialists at 1-800-718-4658. We are currently investigating these side effect cases in all 50 states.

Tekturna was approved for use in the United States and Great Britain in 2007 for high blood pressure. It is part of a new class of drugs called Renin Inhibitors. Renin is an enzyme created by the kidneys which regulates blood pressure. Unfortunately, Renin also raises blood pressureand Tekturna is supposed to stop that event.

Tekturna should not be prescribed to patients who are diabetic and who are taking enzyme ACE inhibitors or receptor blockers.

The new warnings include risks that patients should not use Tekturna if they have diabetes or any type of kidney impairment.

If you would like a confidential free case review please complete the free case review on the right.

The label change was announced on April 20th, 2012 concerning serious risks used by diabetics for patients with kidney failure who are also taking ACE inhibitors or angiotensin receptor blockers (ARBs). Novartis also stated in its announcement that it will remove from the marketplace Valturna, which is a single pill combination of aliskiren and valsartan by July 20, 2012.